Cytostasis

RaySearch acquires the product DrugLog from Pharmacolog for chemotherapy quality assurance

Retrieved on: 
Friday, February 9, 2024
Patient, Calibration, Cytostasis, Software, Sale, Cancer, Acquisition, Intellectual property, Medical imaging

STOCKHOLM, Feb. 9, 2024 /PRNewswire/ -- Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights. The purchase price for the asset acquisition amounts to SEK 7 million.

Key Points: 
  • RaySearch (publ) announces today the acquisition of the product DrugLog™ ️ from Pharmacolog AB.
  • Johan Löf, founder and CEO, RaySearch: "We are excited to welcome DrugLog to RaySearch's product portfolio.
  • DrugLog will be an excellent complement to this and significantly improve and simplify quality assurance in cancer treatment with chemotherapy.
  • Further information regarding the acquisition and integration of DrugLog will be communicated to customers, partners, and stakeholders in the future.

EQS-News: Medios AG: starts successfully into the 2023 financial year

Retrieved on: 
Thursday, May 11, 2023
Gesellschaft mit beschränkter Haftung, AFS, Cytostasis, EBITDA, Acquisition, International business, Climate, ESG, Growth, Environment, Fine chemical, Medio (company)

Berlin, 11 May 2023 – Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, confirms its forecast for the 2023 financial year after a successful first quarter of 2023 with new record revenue; EBITDA pre1 is only slightly below the record level from the third quarter of 2022.

Key Points: 
  • Berlin, 11 May 2023 – Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, confirms its forecast for the 2023 financial year after a successful first quarter of 2023 with new record revenue; EBITDA pre1 is only slightly below the record level from the third quarter of 2022.
  • Consequently, the EBITDA pre1 margin in the first quarter of 2023 was at the level of the prior-year period at 3.5%.
  • For the further course of the 2023 financial year, we expect a continuation of the positive development.“
    In the first quarter of 2023, Medios began offering highly specialized parenteral nutrition care for premature infants nationwide.
  • As a result of the high demand for Specialty Pharma drugs, Medios expects continued dynamic growth in the 2023 financial year.

Lung Cancer Research Foundation Announces New Research Collaboration with Daiichi Sankyo and AstraZeneca

Retrieved on: 
Thursday, March 16, 2023
Research, Lung cancer, Spacecraft, HER2, AstraZeneca, Biomarker, Patient, ADC, Cytostasis, Woman, ET, Disease, NSCLC, Daiichi Sankyo, Doctor of Philosophy, Cancer, Recurrence, Pharmaceutical industry

NEW YORK, March 16, 2023 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) today announced a collaboration with Daiichi Sankyo and AstraZeneca to fund up to three research grants focused on antibody drug conjugates (ADCs) to improve outcomes for people with lung cancer. Applications for these grants are being accepted through May 31, 2023.

Key Points: 
  • NEW YORK, March 16, 2023 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) today announced a collaboration with Daiichi Sankyo and AstraZeneca to fund up to three research grants focused on antibody drug conjugates (ADCs) to improve outcomes for people with lung cancer.
  • This collaboration seeks to support research to study HER2 directed and TROP2 directed ADCs including mechanism of action, biomarkers, and resistance mechanisms.
  • "LCRF is honored to continue its long legacy of identifying and supporting outstanding lung cancer research projects over the years.
  • "The specific focus of this grant program is to further study ADCs and how they might be applied to lung cancer treatment.

Elastomeric Infusion Pumps Market Report 2022: Featuring Baxter International, B. Braun Melsungen, Gamastech, Halyard Health & More - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023
Medical Devices, Health, Disease, Chelation therapy, Hospital, Elastomer, Geography, Conditional sentence, Cytostasis, Growth, Prevalence, Analgesic, Ambulatory care, Pain management, Medical device

Elastomeric infusion pumps are disposable medical used for the administration of liquid drugs such as analgesics, antibiotics, chemotherapy medications, etc.

Key Points: 
  • Elastomeric infusion pumps are disposable medical used for the administration of liquid drugs such as analgesics, antibiotics, chemotherapy medications, etc.
  • For the purpose of this study, the global elastomeric infusion pumps market is studied for various segments based on product types, treatment types, usage areas, and geographical distribution.
  • In terms of geography, North America dominated the global elastomeric infusion pumps market due to greater acceptance of elastomeric infusion pumps, developed healthcare infrastructure, and well organized reimbursement scenarios.
  • Among the considered usage areas, hospitals and clinics currently dominate the global elastomeric infusion pumps market.

Cardiovascular Systems, Inc. Announces First In-Human Experience With Peripheral Everolimus Drug-Coated Balloon

Retrieved on: 
Wednesday, March 9, 2022
Health, Medical Devices, Technology, Other Technology, General Health, Clinical Trials, Cardiology, NASDAQ, Safety, Heart, Cytostasis, Clinical trial, Leg, CSI, Twitter, Medtronic, Annual report, DCB Bank, Private Securities Litigation Reform Act, Physician, Plaque, Peripheral artery disease, FDA, CV, DCB, IDE, LLC, Diabetes, Stent, Medical Affairs Bureau, Testosterone and the cardiovascular system, Form 10-K, Form 10-Q, Pain, News, Acquisition, Risk, Obesity, Hospital, Prevalence, PAD, Patient, Everolimus, Coronary artery disease, COO, SEC, Male, Organization, Amputation, Walking, View, Pharmaceutical industry, MD, SFA, Covidien, CVT, Cardiovascular Systems, Inc., Chansu Vascular Technologies, LLC, Peripheral Artery Disease (PAD), CARDIOVASCULAR SYSTEMS, INC., CHANSU VASCULAR TECHNOLOGIES, LLC, PERIPHERAL ARTERY DISEASE (PAD)

The peripheral DCB was used to successfully treat a 69 year-old male with a 7.5 cm lesion in his superficial femoral artery (SFA).

Key Points: 
  • The peripheral DCB was used to successfully treat a 69 year-old male with a 7.5 cm lesion in his superficial femoral artery (SFA).
  • We believe this promising new generation of everolimus DCBs could improve patient outcomes for those suffering from peripheral artery disease.
  • Jeffery Chambers, M.D., CSIs Chief Medical Officer, said, Following the announcement of the first in-human experience with CVTs coronary everolimus DCB in November 2021, we are thrilled to announce the first in-human experience with the peripheral everolimus DCB.
  • CVT was founded by Philippe Marco, MD, with the exclusive purpose to develop peripheral and coronary DCBs using everolimus.

Cardiovascular Systems, Inc. Announces First In-Human Experience With Coronary Everolimus Drug Coated Balloon

Retrieved on: 
Thursday, November 4, 2021
Health, Medical Devices, Cardiology, Cytostasis, Calcium, Clinical trial, Artery, Plaque, Leg, ISR, Peripheral artery disease, Annual report, Acquisition, CSI, Coronary artery disease, Risk, CV, Form 10-Q, Moyamoya disease, Safety, COO, Form 10-K, CAD, Testosterone and the cardiovascular system, Medtronic, DCB Bank, PCI, Woman, Everolimus, Medical Affairs Bureau, Patient, FDA, View, Private Securities Litigation Reform Act, Organization, Heart, Degenerative disease, NASDAQ, Doctor of Philosophy, Cardiovascular disease, LLC, Twitter, SEC, Man, Atherosclerosis, Stent, Korea Disease Control and Prevention Agency, News, IDE, DCB, MACE, Hospital, Center, Death, Physician, Diabetes, Pharmaceutical industry, Medical imaging, Cardiovascular Systems, Inc., Chansu Vascular Technologies, LLC, Coronary Artery Disease (CAD), CARDIOVASCULAR SYSTEMS, INC., CHANSU VASCULAR TECHNOLOGIES, LLC, CORONARY ARTERY DISEASE (CAD)

Everolimus, the active drug in CVTs DCB formulation, acts as a cytostatic agent to reduce tissue hyperplasia and associated restenosis and has a long history of safety and efficacy in coronary drug-eluting stent applications.

Key Points: 
  • Everolimus, the active drug in CVTs DCB formulation, acts as a cytostatic agent to reduce tissue hyperplasia and associated restenosis and has a long history of safety and efficacy in coronary drug-eluting stent applications.
  • Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.
  • CVT was founded by Philippe Marco, MD, with the exclusive purpose to develop peripheral and coronary DCBs using everolimus.
  • CSI is a registered trademark of Cardiovascular Systems, Inc. All other trademarks cited herein are owned by their respective owners.

Global Metastatic Breast Cancer Pipeline Insight Report 2021: Focus on 100+ Companies and 100+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, October 18, 2021
General Health, Health, Oncology, Other Health, Cytostasis, Paclitaxel, Endothelium, II, Allar, Jerusalem, SERD, Drug resistance, Metastatic breast cancer, Growth, Discovery, PARP, Roche, Therapy, Enzyme, ADC, Clinical trial, News, ESR1, CDE, Lipid, BBB, Toxicity, DRP, Poly (ADP-ribose) polymerase, Mergers and acquisitions, Neoplasm, ER, III, Medical imaging, Pharmaceutical industry, Dietary supplement

This "Metastatic Breast Cancer - Pipeline Insight, 2021" report provides comprehensive insights for about 100+ companies and 100+ pipeline drugs in Metastatic Breast Cancer pipeline landscape.

Key Points: 
  • This "Metastatic Breast Cancer - Pipeline Insight, 2021" report provides comprehensive insights for about 100+ companies and 100+ pipeline drugs in Metastatic Breast Cancer pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Breast Cancer R&D.
  • The therapies under development are focused on novel approaches to treat/improve Metastatic Breast Cancer.
  • This segment of the Metastatic Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.